Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anne-Kathrin Garz
Observed names:
A.K. Garz,
Garz, A.-K.
Institutions:
TUM Klinikum,
Technical University of Munich
Observed institutions:
German Cancer Research Center,
TUM Klinikum,
Deutsches Konsortium für Translationale Krebsforschung,
Technical University of Munich
OpenAlex ID:
A5079769684
The target landscape of clinical kinase drugs
2017
·
Susan Klaeger
, Stephanie Heinzlmeir
, et al.
·
Science
·
913
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
2016
·
Jeannine Diesch
, Anabel Zwick
, et al.
·
Clinical Epigenetics
·
196
PDF
Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity
2016
·
Ruth Eichner
, Michael Heider
, et al.
·
Nature Medicine
·
194
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
2021
·
Michael Heider
, Ruth Eichner
, et al.
·
Molecular Cell
·
62
PDF
Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis
2018
·
Catharina Wenk
, Anne-Kathrin Garz
, et al.
·
Blood Advances
·
52
Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations
2017
·
Anne-Kathrin Garz
, Saskia Wolf
, et al.
·
Oncotarget
·
17
PDF
Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes
2017
·
Anna Palau
, Anne-Kathrin Garz
, et al.
·
Oncotarget
·
7
PDF
34 Azacitidine Directly Modulates Function of Mesenchymal Stromal Cells to Alter Bone Marrow Niche Compostion and Suppress Malignant Hematopoeitic Progenitors in Mds
2015
·
C. Huberle
, C. Wenk
, et al.
·
Leukemia Research
·
3
Azacitidine Directly Acts on the Mesenchymal Stromal Cell Compartment in Myelodysplastic Syndromes to Alter Niche Function and Suppress Malignant Hematopoeitic Stem/Progenitor Cells
2017
·
Catharina Wenk
, Anne-Kathrin Garz
, et al.
·
Blood
·
1
Azacitidine in Combination with the Selective FLT3 Kinase Inhibitor Crenolanib Effectively Disrupts Stromal Protection of CD34+ Leukemia-Initiating Cells (LIC) in FLT3-ITD+ Acute Myeloid Leukemia (AML)
2015
·
Anne-Kathrin Garz
, Stefan Habringer
, et al.
·
Blood
·
1
The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism
2019
·
Michael Heider
, Ruth Eichner
, et al.
·
Blood
Polycomb Protein RING1A Limits Differentiation in Myelodysplastic Syndromes
2017
·
A. Palau
, A. Zwick
, et al.
·
Leukemia Research
Azacitidine combined with crenolanib abrogates niche protection and expansion of residual leukemic stem cells (LSC) in FLT3-ITD+ acute myeloid leukemia (AML) with concurrent gene mutations in NPM1, DNMT3A or TET2
2017
·
Anne-Kathrin Garz
PDF
Significantly Reduced CFU-F Frequency and Increased Adipogenic Differentiation of Mesenchymal Stem Cells (Msc) in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
2017
·
Marie‐Theresa Weickert
, Anne-Kathrin Garz
, et al.
·
Annals of Hematology
Frequency and clonogenic capacity of the rare CFU-F subpopulation of Mesenchymal Stem Cells (MSC) is significantly reduced in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
2016
·
Marie‐Theresa Weickert
, Anne-Kathrin Garz
, et al.
Show more works
View as search
Works count:
17
Citation count:
1,446
H-index:
7
I10-index:
6
Year
Topic
Type